Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals, Inc. is a leading innovative and rare disease pharmaceutical company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade.
OTCQX: MEDFX
TSX: MDP
IR Website: https://www.medexus.com/en_US/investors
Headquarters: Bolton, Ontario, Canada
Content provided by Medexus Pharmaceuticals on 2/24/22.
TALK TO MANAGEMENT
The Medexus Pharmaceuticals management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Medexus Pharmaceuticals, Inc. is a leading innovative and rare disease pharmaceutical company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade.
Investor Presentation
Recent News
Medexus Pharmaceuticals Announces Deal for Gleolan in the United States
Mar 1, 2022
Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures
Feb 14, 2022
Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021
Feb 9, 2022
Medexus to Present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference
Feb 1, 2022
Medexus Schedules Third Quarter Fiscal 2022 Conference Call
Jan 31, 2022
Medexus to Present at the H.C. Wainwright BioConnect 2022 Conference
Jan 7, 2022
Management Overview
Ken d'Entremont
Chief Executive Officer and Director
Ken d’Entremont is the founder, president, and CEO of Medexus Inc. Previously, he was the general manager and vice president of business development at Sanofi, where he led the in-licensing initiatives for Sanofi Canada. Mr. d’Entremont holds a Bachelor of Science in Chemistry from McMaster University.
Marcel Konrad
Chief Financial Officer
Marcel Konrad joined Medexus in 2021 from CareDx, Inc. (Nasdaq: CDNA), a precision medicine solutions company, where he served as Senior Vice President Finance & Accounting and Vice President, Corporate Controller. Mr. Konrad brings over 20 years of experience in Accounting, Finance and Business across various global markets that include Chief Financial Officer at Santen Inc, a US subsidiary of Santen Pharmaceuticals, a Japanese eye care company and various roles at Novartis both in the US and Switzerland. Mr. Konrad was an Auditor with KPMG. He holds an International MBA from the University of San Diego and has a Masters of Business Administration from HEC Lausanne, Switzerland. Mr. Konrad is an active US CPA.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Medexus Pharmaceuticals Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
